Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29713811 | 1.00 | RXFP1 (0.47) | RXFP1CYP1A2CYP2A6ALDH1A1HSD17B10 | |
| Ethoxycarbonyl Group SCHEMBL27551543 | 0.80 | NR3C1 (0.35) | RXFP1CYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL29507097 | 0.78 | AHR (0.45) | RXFP1CYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL1019021 | 0.78 | AHR (0.45) | RXFP1CYP1A2ALDH1A1HSD17B10HPGD | |
| SCHEMBL915763 | 0.78 | RPS6KA3 (0.40) | RXFP1CYP1A2ALDH1A1HSD17B10HPGD | |
| SCHEMBL24037999 | 0.78 | ALDH1A1 (0.37) | RXFP1CYP1A2ALDH1A1HSD17B10HPGD | |
| SCHEMBL1019925 | 0.78 | AHR (0.45) | RXFP1CYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL827753 | 0.78 | RHEB (0.50) | ALDH1A1HSD17B10HPGDALOX15AHR | |
| SCHEMBL12113048 | 0.78 | ALDH1A1 (0.37) | RXFP1CYP1A2ALDH1A1HSD17B10HPGD | |
| SCHEMBL15826435 | 0.78 | RHEB (0.50) | ALDH1A1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113045724-B | Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-113045724-A | Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-109485650-A | The method of level-one amine guiding building 8,10- dimethyl -6- Phenylindole simultaneously [1,2-a] quinoxaline | 桂林理工大学 | 2019-03-19 | — | — | CN | claimed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023116594-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海安诺达生物科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2022268025-A1 | ATR INHIBITOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| CN-113045724-B | Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| WO-2021144440-A1 | QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
| CN-113045724-A | Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| JP-2002053552-A | METHOD FOR PRODUCING 4,6-DIMETHYLINDOLE AND DERIVATIVE THEREOF | SANKYO CO LTD | 2002-02-19 | — | — | JP | disclosed |
| EP-0866059-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF | KYOTO PHARMA IND (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-1136474-A1 | 1-Acetyl-5-bromo-4,6-dimethyl-indoline | SANKYO COMPANY LIMITED (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-6200988-B1 | TETRAHYDROQUINOLINE DERIVATES; INHIBITORS OF ACYL COA:CHOLESTEROL ACYLTRANSFERASE AND LIPOPEROXIDATION; ARTERIOSCLEROSIS: CARDIOVASCULAR AND BRAIN DISORDERS | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| US-6127403-A | AN ENZYME INHIBITOR FOR TREATING ARTERIOSCLEROTIC LESIONS OF ARTERIOSCLEROSIS, HYPERLIPEMIA AND DIABETES, AS WELL AS ISCHEMIC DISEASES OF BRAIN, HEART | SANKYO COMPANY, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6063806-A | CARBOXY ACID OR ESTER DERIVATIVES OF INDOLINE OR INDOLE | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-05-16 | — | — | US | disclosed |
| US-5990150-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS AND LIPOPEROXIDATION INHIBITORY ACTIVITY; ANTILIPEMIA; ARTERIOSCLEROSIS; ANTICHOLESTEROL AGENTS; ANTIISCHEMIC AGENTS; SIDE EFFECT REDUCTION | SANKYO COMPANY, LTD. (JP) | 1999-11-23 | — | — | US | disclosed |
| EP-0866059-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1998-09-23 | — | — | EP | disclosed |
| EP-0782986-A1 | NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1997-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | RXFP1 2568/4885CYP1A2 4272/4885CYP2A6 3027/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | RXFP1 2568/4885CYP1A2 4272/4885CYP2A6 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.